Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward, according to a study.  While patients reported a decline in these quality of life measures immediately after brachytherapy, they achieved a full recovery within six months. Brachytherapy involves inserting radioactive seeds in or near tumor to kill it.  The research, “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131,” was published in the Journal of Radiation Oncology, Biology, Physics.  “This study reinforces the position of Cesium 131 as an effective, patient-friendly treatment for localized prostate cancer,” Bill Cavanagh, chief scientific officer of the brachytherapy company IsoRay, said in a news release. “This is especially important as multiple studies are emerging that strongly suggest that the inclusion of brachytherapy must be considered for the treatment of high-risk prostate cancer – the toughest localized prostate cancer to cure.”  Read more.

Source: Prostate Cancer News Today, May 4, 2017